The impact of second-line agents on patients' health-related quality of life in the treatment for non-small cell lung cancer: a systematic review.

about

Nintedanib for the treatment of patients with advanced non-small-cell lung cancer.

P2860

Q38239545-70C3E8F3-173A-44C2-B699-A4539ED2BF43

P2860

The impact of second-line agents on patients' health-related quality of life in the treatment for non-small cell lung cancer: a systematic review.

Item

http://www.wikidata.org/entity/Q38027080

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

The impact of second-line agen ...... g cancer: a systematic review.

@en

type

Item

label

The impact of second-line agen ...... g cancer: a systematic review.

@en

prefLabel

The impact of second-line agen ...... g cancer: a systematic review.

@en

P1476

The impact of second-line agen ...... g cancer: a systematic review.

@en

P2093

Arijit Ganguli

http://www.w3.org/2001/XMLSchema#string

John A Carter

http://www.w3.org/2001/XMLSchema#string

Marc F Botteman

http://www.w3.org/2001/XMLSchema#string

Phillip Wiegand

http://www.w3.org/2001/XMLSchema#string

Saurabh Ray

http://www.w3.org/2001/XMLSchema#string

Xin Gao

http://www.w3.org/2001/XMLSchema#string

P2860

2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer

Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group.

Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy.

Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews.

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

P2888

s11136-012-0229-0

P304

1015-1026

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11136-012-0229-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-07-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

229160704

http://www.w3.org/2001/XMLSchema#string

P698

22806607

http://www.w3.org/2001/XMLSchema#string

P921

quality of life

The impact of second-line agents on patients' health-related quality of life in the treatment for non-small cell lung cancer: a systematic review.

about

P2860

P2860

The impact of second-line agents on patients' health-related quality of life in the treatment for non-small cell lung cancer: a systematic review.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P698

P921